Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14

CUMBERLAND PHARMACEUTICALS INC

FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.
Q4 revenue $9.1M; net loss $2.4M; adj. loss $0.7M ($0.05/sh) vs adj. loss $1.9M in Q4 2021.
Cash from operations $8.5M vs $6.3M prior year; balance sheet: $20M cash, $57M liabilities, $36M equity.
Product revenue: Kristalose $15.2M, Sancuso $13.2M, Vibativ $7.5M, Caldolor $4.8M.
Acquired Sancuso from Kyowa Kirin in 2022; new Nashville HQ; international partnerships for Vibativ and Caldolor.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC reported full year 2022 results: revenue Net revenues were $42.0 million, net income Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year., EPS $0.38 per share.

Period: full year 2022
Revenue: Net revenues were $42.0 million
Net income: Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year.
EPS: $0.38 per share
Result: reported results

Exact text from the filing

(NASDAQ: CPIX) , a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were

View on SEC.gov

Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-23-006782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.